ALLERGY THERAPEUTICS PLC

Declaration of Voting Results & Voting Rights Announcements • Oct 1, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1606T

Allergy Therapeutics PLC

01 October 2014

1 October 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Total Voting Rights

Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces the Company's share capital consists of 410,055,331 Ordinary 0.1p shares with voting rights attached (one vote per Ordinary share). The Company has no shares in Treasury therefore the total number of voting rights in Allergy Therapeutics is 410,055,331.

The above total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Allergy Therapeutics under the FCA's Disclosure and Transparency Rules.

For further information

Allergy Therapeutics	+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director
Peel Hunt LLP	+44 (0) 20 7418 8900
James Steel Clare Terlouw
FTI Consulting	+44 (0) 20 3727 1000
Simon Conway Victoria Foster Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the current financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVREAFEFEANLFFF